

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/116680>

**How to cite:**

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk).

**Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy?**

Li-li Cui, MD, PhD<sup>1, 2</sup>; Dominika Golubczyk, MSci<sup>3</sup>; Anna-Maija Tolppanen, PhD<sup>4</sup>; Johannes Boltze, MD, PhD<sup>5,\*</sup>; Jukka Jolkkonen, PhD<sup>2, 6,\*,#</sup>

1. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China

2. Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland

3. Department of Neurosurgery, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland

4. School of Pharmacy, University of Eastern Finland, Kuopio, Finland

5. School of Life Sciences, University of Warwick, Coventry, UK

6. Neurocenter, Kuopio University Hospital, Kuopio, Finland

\*Drs Boltze and Jolkkonen contributed equally.

**Running head:** Cell therapy for ischemic stroke

**#Corresponding address:**

Institute of Clinical Medicine-Neurology

University of Eastern Finland

Yliopistonranta 1C (P.O.Box 1627), 70211 Kuopio, Finland

Telephone: +358-40-3552519

Email: [jukka.jolkkonen@uef.fi](mailto:jukka.jolkkonen@uef.fi)

**Character count of title: 142**

**Character count of running head: 32**

**Word count of abstract: 99**

**Word count of the body of manuscript: 3829 (<4000)**

**Number of figures: 7**

**Number of color figures: 1**

**Number of tables: 0**

## **ABSTRACT**

Cell therapy is an attractive strategy for enhancing post-stroke recovery. Different cell types and several treatment strategies have been successfully applied in animal models, but efficacy in stroke patients has not yet been confirmed. We hypothesize that the significant design differences between preclinical and clinical trials may account for this situation. Using a meta-analysis approach and comparing preclinical with clinical trials, we reveal and discuss preliminary evidence for such design differences. While available datasets are not yet numerous enough to draw definitive conclusions, these findings may represent signposts on the route to efficacy by harmonizing preclinical and clinical study designs.

48    **Abbreviations**

49	ART	adhesive removal test
50	BBB	blood-brain barrier
51	CI	confidence intervals
52	FMS	Fugl-Meyer Scale
53	mBI	modified Barthel Index
54	MSC	mesenchymal stem/stromal cell
55	MNC	mononuclear cell
56	mNSS	modified neurological severity score
57	mRS	modified Rankin Scale
58	NIHSS	National Institutes of Health Stroke Scale
59	NRCT	non-randomized controlled trial
60	NSC	neural stem cell
61	PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
62	RCT	randomized controlled trial
63	SMD	standardized mean differences
64	T1DM	type 1 diabetes mellitus
65	T2DM	type 2 diabetes mellitus
66		

Cell-based therapy has been proposed as a promising paradigm for ischemic stroke for almost two decades<sup>1</sup>. Different types of cells, particularly mesenchymal stem/stromal cells (MSCs), neural stem cells (NSCs) and mononuclear cells (MNCs), have been successfully tested in animal models. Several mechanisms, such as (limited) cell replacement, immunomodulation, as well as promotion of angiogenesis and neurogenesis, have been claimed to be responsible for the observed improvements<sup>2-4</sup>.

Although a number of early-phase clinical studies investigating cell therapy for ischemic stroke have been conducted, convincing evidence of efficacy is still lacking<sup>5-8</sup>. Inadequate quality of preclinical tests has been previously considered as a major reason for unsuccessful translation of experimental stroke therapies into the clinic, but the quality of preclinical stroke studies is clearly improving<sup>9</sup>. However, significant design differences between preclinical and clinical trials may hinder translation. Hence, it is essential to explore how well the currently described preclinical and clinical trial designs correspond to each other in order to devise innovative ways for advancing clinical translation of cell therapies in stroke.

An objective way to approach such problems is to conduct a systematic meta-analysis. Therefore, we have adopted this approach to: 1) estimate the current cell therapy efficacies in both animal stroke models and stroke patients; 2) explore the sources of heterogeneity in preclinical and clinical studies; 3) investigate the hypothesis of poorly-corresponding preclinical and clinical trial designs; and 4) identify the potential gaps in clinical translation to be bridged in future approaches.

### Methodological approach

Studies on cell therapy for ischemic stroke published before April 3<sup>rd</sup> 2018 were identified from PubMed, Web of Science, and Scopus according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The detailed protocol is available on PROSPERO (CRD42018093214 and CRD42018096257) or in Supplemental Material. Briefly, preclinical studies describing cell transplantation in animal models of focal cerebral ischemia, and controlled clinical studies were gathered. We included the four most frequently examined outcome measures: 1) infarct size; 2) modified Neurological Severity Score (mNSS); 3) rotarod test; and 4) adhesive removal test (ART) performance. A quality score was also assigned<sup>10,11</sup>. In clinical studies, functional outcomes were measured by National Institutes of Health Stroke Scale (NIHSS), modified Barthel index (mBI), modified Rankin scale (mRS), and Fugl-Meyer scale (FMS). Standardized mean differences (SMD), 95% confidence intervals (95% CI) and statistical significances were examined using the inverse-variance method<sup>12</sup>. For each outcome, the effect size was calculated using *Hedges' g* and heterogeneity was calculated as  $I^2$ . In view of the substantial heterogeneity in the included studies, a random effects model was applied to estimate the pooled effect size. Univariate meta-regression was conducted on preclinical studies and subgroup analysis was conducted on clinical studies to explore the sources of heterogeneity.  $P < 0.05$  was considered as statistically significant and  $0.05 \leq P < 0.10$  as a trend. Data were analyzed using Stata version 14.0 (Stata-Corp).

A total of 3868 records from PubMed, 5041 records from Scopus, and 4073 records from Web of Science were identified. Ultimately, 355 preclinical studies with 10830 animals, and 10 controlled clinical studies (phase I/II) with 460 patients were included (Fig 1).

### Preclinical and clinical study qualities

The median quality score of the preclinical studies was 5 out of 10 (interquartile range: 4-6) (Online Table 1). Randomization and blinded outcome assessment had been applied in 222 (62.5%) and 203 (57.2%) of the 355 included studies, respectively. Only 23 (6.5%) studies reported allocation concealment and 10 (2.8%) studies provided a *priori* sample size

calculation. Animal models with comorbidities such as hypertension or diabetes were utilized in only 24 (6.8%) studies.

Nine out of the ten clinical trials had at least one source of bias according to the Cochrane Risk of Bias Tool<sup>13</sup>. Four studies were non-randomized controlled trials (NRCT), five studies did not report allocation concealment, and five studies featured a non-blinded outcome assessment. Only one trial was double-blinded. All studies reported complete outcome data, but only two provided details regarding power calculation.

## **Therapeutic effect differences in cell therapy**

### ***Robust efficacy of cell therapy in stroke animals***

Analysis of published data confirmed previous findings that cell therapy significantly improved both structural and functional outcomes in experimental stroke<sup>14-18</sup>. Although substantial inter-study heterogeneities ( $I^2$ ) were observed (65.7%-75.2%), the effect size was consistently large for each outcome measure (1.35 for infarct size reduction, 1.69 for mNSS, 1.56 for rotarod test, and 1.56 for ART;  $P < 0.001$ , Fig 2).

Funnel plotting suggested that there was a significant left-sided bias, meaning that studies with effect sizes smaller than mean values were under-reported (Fig 3). Egger's regression test revealed a significant publication bias for each outcome ( $P < 0.01$ ). Nonetheless, after adjusting for publication bias by trim and fill, the mean effect sizes remained large (0.79 for infarct size, 1.09 for mNSS, 1.00 for rotarod test and 1.07 for ART).

### ***Potential reasons for therapeutic effect heterogeneity in preclinical studies***

The immunogenicity of injected cells accounted for 5.3%-16.0% of the observed heterogeneity in outcome ( $P < 0.05$ ). Based on the results of infarct size and ART, autologous cells had the largest effect, followed by allogeneic and xenogeneic cells; syngeneic cells did not display any significant efficacy in comparison with control treatment (Fig 4Ai, Ci, Di).

Freeze-thawing procedure accounted for up to 9.9% of the observed heterogeneity, e.g. in ART performance ( $P < 0.01$ ). Freshly-isolated cells were consistently associated with larger effects than frozen-thawed cells (Fig 4Aii, Bi, Dii).

Cell type accounted for 7.6% of the observed heterogeneity in functional outcome (rotarod test) ( $P = 0.0075$ ). Treatment with NSCs showed the largest effect, followed by MSCs, MNCs, and other cells (Fig 4Ci). Cell origin, cell stemness and manipulation also contributed to the heterogeneity (Supplemental Fig 1B-E).

Comorbidities also influenced outcome and explained 1.3%-5.8% of the observed heterogeneity ( $P < 0.05$ ). Cell treatment of comorbid animals consistently induced smaller effects than those obtained in healthy animals (Fig 4Aiii, Bii, Diii).

The stroke model accounted for 2.3% of the observed heterogeneity in infarct size ( $P = 0.0407$ ). The intraluminal filament model was associated with the largest therapeutic effects (Fig 4Aiv). Moreover, an earlier assessment of infarct size (within one month) revealed larger effects as compared to a later assessment, suggesting that the therapeutic effect of injected cells may decline with time (Supplemental Fig 1A).

The cell delivery route accounted for 8.1% of the observed heterogeneity in infarct size ( $P = 0.0001$ ). Intraventricular cell delivery achieved the largest effects on infarct size (Fig 4Av), but intracortical cell transplantation induced the greatest impact on mNSS performance, followed by intraventricular cell delivery (Fig 4Biii).

A higher quality score tended to result in a smaller effect size ( $P = 0.09$ ) (Fig 4Biv). A higher impact factor of the published journal also tended to associate with a smaller effect size ( $P = 0.0961$ ) (Supplemental Fig 1F).

### ***Moderate cell therapy efficacy in patients***

Despite the small number of clinical trials, cell therapy induced a statistically significant beneficial effect in mBI (SMD=0.32, 95% CI: 0.03-0.61, P=0.032) as well as a trend in mRS (SMD=0.30, 95% CI: -0.03-0.64, P=0.078), but not in NIHSS (P=0.298) or FMS (P=0.112). The heterogeneity varied considerably with the various outcome measures (24.3%-85.0%) (Fig 5).

### ***Potential reasons for therapeutic effect heterogeneity in clinical trials***

We performed further subgroup analyses to clarify the effects of different clinical study design characteristics (Fig 6). MSCs showed a larger effect size than MNCs in mRS (0.20 vs. 0.07; Fig 6Ai), mBI (0.94 vs. 0.13; Fig 6Bi), and FMS (1.77 vs. 0.35; Fig 6Di). Allogeneic/cryopreserved cells had been administered in only one study. Similar to the preclinical findings, studies using autologous/freshly-harvested cell therapy achieved better outcomes than those utilizing allogeneic/cryopreserved cells in mRS (0.37 vs. 0.17; Fig 6Aii, 6Aiii), mBI (0.39 vs. 0.23; Fig 6Bii, 6Biii), and NIHSS (0.88 vs. -0.02; Fig 6Cii, 6Ciii). Furthermore, a trial using intracortical cell delivery reported better outcomes as compared to intravascular delivery in mRS (Fig 6Aiv) and NIHSS (Fig 6Civ). Randomized clinical studies revealed larger effect sizes than non-randomized ones in mRS (0.37 vs. 0.22; Fig 6Av) and NIHSS (0.78 vs. 0.08; Fig 6Cv), but smaller effect sizes in mBI (0.28 vs. 0.42; Fig 6Bv) and FMS (0.52 vs. 0.80; Fig 6Dv).

### ***Preclinical and clinical study design differences: current situation and potential impact***

In contrast to the very positive results in animal models, therapeutic effects in clinical studies have been less impressive. It is noteworthy that current clinical studies on cell therapy for stroke are early stage clinical trials and are often underpowered to reveal all but the most prominent therapeutic effects. Nevertheless, remarkable design differences between preclinical and clinical studies were detected (Fig 7), which may affect clinical translation. Interestingly, we already identified cell immunogenicity, cryopreservation, cell type, comorbidity profiles and occlusion modality (i.e., the stroke model) as sources of effect size heterogeneity in preclinical studies. Basic preclinical study design characteristics are described in Online Table 2, and those of clinical studies are in Online Table 3.

### ***Cell immunogenicity***

The majority of the cells used in preclinical studies were allogeneic (47.9%) or xenogeneic (46.2%), but most of the clinical studies have utilized autologous cell transplants (70.9%) (Fig 7A). In line with another analysis<sup>16</sup>, autologous cells have achieved better outcomes than their allogeneic counterparts in preclinical and clinical studies. Therefore, cell immunogenicity may not be a major reason for the current translational loss of efficacy. However, autologous cells were used in 25 preclinical studies, while allogeneic cells were used in only one clinical trial, and thus these results need to be interpreted with caution. Interestingly, syngeneic cells only demonstrated minor treatment effects. This contradictory result may be due to the small number of these studies and their high quality scores (median: 9 as compared to 5 for the entire data set).

Autologous cell therapy avoids adverse immunological side effects after transplantation, which is clinically relevant. The effect of systemic xenogeneic cell transplantations in preclinical experiments may theoretically be related to the immunosuppressive effects of apoptotic cells diminishing secondary inflammatory brain damage. This idea was proposed more than two decades ago<sup>19</sup>, but has never been truly investigated in a stroke paradigm. If this concept is true, its clinical impact would be substantial and clearly warrants future investigation.

## **Cryopreservation**

In preclinical studies, 33.1% of stroke animals received freshly harvested cells, 10.3% received cryopreserved cells, while no clear details on cryopreservation were provided in the other studies. In clinical trials, freshly harvested cells were used in 70.9% of patients with cryopreserved cells being used in the remainder (Fig 7B). The exploitation of cryopreserved cells as off-the-shelf products allows cell delivery at acute time points. However, our results indicate that frozen-thawed cells were associated with significantly reduced efficacy when compared to their freshly-harvested counterparts in preclinical and clinical trials. Cryopreserved cells may indeed exhibit lower viability, compromise immunomodulatory effects, and induce more intense or immediate blood-mediated inflammatory reactions<sup>20-23</sup>, particularly in MNC populations<sup>23</sup>. Nonetheless, some recent studies have also described comparable therapeutic effects between cryopreserved and fresh cells<sup>24-26</sup>. The exact conditions compromising the efficacy of cryopreserved cells may be complex but should be clarified as soon as possible.

## **Cell type**

MSCs were the most frequently investigated cells in preclinical studies (51.5% of stroke animals), followed by NSCs (21.8%), and MNCs (14.9%) (Fig 7C). Other cells such as endothelial progenitors, induced pluripotent or embryonic stem cells, had been administered in 11.9% of stroke animals. In contrast, MNCs were much more frequently given to stroke patients (55.2%). Six out of ten included clinical studies used heterogeneous MNC populations, three administered MSCs, and one utilized CD34<sup>+</sup> cells.

The optimal cell type for ischemic stroke treatment remains unclear. Our analysis pointed to a superior effect with MSCs as compared to MNCs in both preclinical and clinical trials. The predominant use of MNCs in the clinic is likely due to practical issues such as ease of isolation and availability without time-consuming and sensitive in vitro cultivation, as well as the excellent safety profile of MNCs, compensating for their potentially lower efficacy. However, one meta-analysis of bone marrow-derived MNCs<sup>17</sup> showed an effect size larger than that achieved with either MSCs<sup>16</sup> or NSCs<sup>18</sup>, perhaps due to the different data searching and inclusion criteria. Analysis of preclinical studies also revealed that the trial with the overall most significant improvement involved NSCs (Fig 4Ciii), but unfortunately no clinical study on NSC transplantation could be included here due to the lack of appropriate control groups<sup>7,27</sup>.

## **Recipient comorbidities**

More than 90% of animals were healthy before stroke induction whereas many stroke patients suffered from comorbidities such as hypertension (38.3%), diabetes (25.2%), and heart disease (30.7%). Only 5.4% of the patients were reported as being healthy before the stroke event (Fig 7D). Comorbidities themselves may exert a detrimental impact on treatment efficacy<sup>28</sup>, as confirmed also in our study. Furthermore, stroke patients often take medications such as anti-diabetics to counter comorbidities, and these compounds may interact with injected cells<sup>29,30</sup>. In addition, stroke patients are usually prescribed anti-platelet drugs for secondary stroke prevention and undergo post-stroke rehabilitation. However, few preclinical studies have investigated these potential interactions, leaving a clear knowledge gap in translational stroke research that likely affects the results obtained in subsequent clinical trials.

Mimicking the complex reality of clinical patient populations in preclinical studies is expensive and time-consuming. A potential solution might be to focus on patients with a particular, more specific risk profile and to mimic that experimentally. The disadvantage of this approach will be a slower patient recruitment as only a subgroup would receive treatment, but comparability will be higher.



### ***Recipient sex and age***

Cell therapy has been mainly provided to young (93.7%) male (85.1%) rodents (99.3%). In contrast, stroke patients were often middle-aged (40-60 years old, 54.8%) or elderly (>60 years old, 45.2%), consisting of both males and females, and were always enrolled in clinical trials without selection (Fig 7E-F). We did not find sex and age to significantly affect the efficacy of cell therapy in stroke animals. However, this kind of influence cannot be excluded simply due to the very limited number of studies assessing female and aged individuals. Indeed, gender-related differences are a well-known and frequently discussed confounder for outcome in translational stroke research<sup>31</sup>. While simulating a clinically realistic sex distribution pattern in preclinical studies requires significant additional resources, neglecting sex differences introduces one more bias into experimental results<sup>32</sup>. Moreover, there is experimental evidence that cell donor's and recipient's ages can influence cell treatment efficacy, particularly in commonly applied MNC populations<sup>33</sup>.

### ***Cerebral vessel occlusion modalities***

The intraluminal filament stroke model was used in 80.5% of the studied animals. As shown above, the use of this model is associated with a larger effect size. It is also characterized by an extremely large infarct size limiting recovery processes, which is similar to the situation after large territorial infarction in humans. About 10-20% of ipsilateral corticospinal fibers do not cross in rodents, cats or monkeys, but it remains rather uncertain whether there are functionally relevant non-crossing corticospinal fibers in adult humans<sup>34</sup>. Hence, the large effect size in preclinical studies employing the filament model may be partly due to the rapid spontaneous stroke recovery mediated via activation and strengthening of the ipsilateral corticospinal pathway<sup>35</sup>, a process that can be further enhanced by cell therapy in rodents – but possibly not in humans.

Moreover, 74.1% of the stroke modelling in preclinical studies was transient, which mimics the recanalization in patients achieved by thrombectomy<sup>36</sup>, thrombolysis, or that occurring spontaneously. However, only a limited number of patients experience prompt recanalization, thus the permanent occlusion models might better reflect the present-day clinical situation except for intra-arterial cell transplantation<sup>5,37,38</sup>. The current advances in recanalization approaches may lead to increasing numbers of patients receiving cell therapy immediately after recanalization in the future, warranting the use of a transient stroke model for preclinical evaluation regardless of the targeted time point of cell administration, and would allow cell transplantation in a more acute stage after stroke-onset in clinical trials.

### ***Time window of cell transplantation***

In the preclinical studies, cells were transplanted within 24h after stroke onset in 67.5%, and between 24h and 1 week in 28.2% of experiments. However, in clinical trials, cells were more often transplanted at later time points, i.e. one week or even one month after stroke-onset (67.3%). No study had transplanted cells within 24h post-stroke (Fig 7G). Cell delivery in acute phase post-stroke is considered to result primarily in neuroprotection via enhanced blood-brain barrier (BBB) integrity and modulation of post-ischemic immune responses, but it is challenging to administer cells so early in the clinic. Post-acute cell delivery potentially increases angiogenesis, neurogenesis, and axonal plasticity, offering a wider time window for cell therapies<sup>39</sup>.

Although the time window was not found here to affect efficacy significantly, many preclinical studies claimed that earlier transplantation of cells could result in a better outcome<sup>40-42</sup>, although no conclusive evidence has been reported<sup>16,43,44</sup>. Successful clinical stroke care involves several strictly timed therapeutic interventions, dramatically restricting the time available for complex cell treatments. For this reason in clinical trials, cells have usually been

transplanted in either the subacute or chronic post-stroke stages. A good example is the MASTERS trial that evaluated the MultiStem cell product<sup>8</sup>, which is one of the best characterized cell products in the field. The preclinical research on the MultiStem cell product revealed an excellent outcome (effect size=3.98 for infarct size and 3.00 for mNSS)<sup>45</sup>, but only modest results were observed in the clinical MASTERS trial<sup>8</sup>. It is noteworthy that the time window for patient inclusion was expanded from 36h to 48h due to logistical requirements beyond the investigators' and sponsor's control. Although the safety of cell transplantation was demonstrated in the final MASTERS clinical trial, no significant therapeutic effect was detected after intravenous cell infusion at 24-48h post-stroke. However, a *post-hoc* subgroup analysis revealed beneficial effects of cell transplantation at earlier time points (<36h), which is exactly the patient population assumed to benefit most according to the preclinical data. The currently ongoing MASTERS-2 trial will take this aspect into account. This supports our proposal that understanding the timing and mechanisms of improvement following cell therapy is essential for successful clinical translation.

### ***Delivery route***

Intravenous cell delivery had been performed in 51.6% of the preclinical studies, and was also predominantly chosen in clinical trials (74.9%). While intravenous cell delivery is a straightforward approach in both preclinical and clinical arenas, the optimal cell delivery route remains unclear and is likely related to the cell type used. Vu et al.<sup>16</sup> reported better mNSS performance after intracortical MSC delivery as compared to intra-arterial and intravenous delivery, whereas Lee et al.<sup>14</sup> found no significant effect of cell delivery route on outcome. Both preclinical and clinical data revealed better outcome of intracortical cell delivery compared to intravascular delivery. However, the utility of intracortical delivery is limited clinically due to its invasiveness<sup>46</sup>. Proof-of-concept studies may be required to assess whether the advantage of intracortical delivery outweighs the safety concerns. Indeed, the recent phase 2b study (NCT02448641) of SB623 (transiently transfected MSCs overexpressing Notch-1) showed safety, but failed to show efficacy in chronic stroke patients, in contrast to the preliminary signs of efficacy from the preceding animal study<sup>47</sup> and phase 1/2b clinical trial<sup>48</sup>. Another sham controlled trial, the recently-started PISCES 3 trial (NCT03629275) is utilizing intracranial transplantation as well, but with a different cell product, cell dose and primary outcome measures; its results are keenly anticipated. The preclinical analysis also revealed superior effects of intraventricular over intracortical cell delivery. The intraventricular route is also slightly easier to perform than intracortical administration while still bypassing the BBB, and thus may be a promising option for the future. However, the potential risk of adverse effects such as hydrocephalus must be considered. No significant difference in therapeutic effect was found between studies using intra-arterial and intravenous delivery routes, but improper intra-arterial cell administration can trigger complications<sup>20, 49, 50</sup>.

### ***Methodological limitations***

We included studies using different cell types, administration modes, etc., which increased the sample size for data analysis, particularly for clinical studies, and also enabled us to explore the sources of heterogeneity. As expected, substantial inter-study heterogeneity was observed. We addressed this in several ways: first, the heterogeneous outcome measures were standardized; second, a random-effects model was used, assuming that the treatment effect can vary across studies because of differences in study characteristics rather than by chance<sup>51</sup>; third, meta-regressions or subgroup analyses were performed to identify the sources of heterogeneity<sup>52,53</sup>. However, unexplained heterogeneity from sources that were not considered in our analysis may remain. It is noteworthy that heterogeneity cannot be avoided, and

considerable heterogeneity was also observed in previous studies using more strict inclusion criteria<sup>16-18</sup>.

Moreover, the number of included clinical studies is still small. In some cases, there was only one study (e.g. allogeneic/cryopreserved) available for subgroup analysis. Thus, the validity of these results remains uncertain, and more clinical results are needed.

## Conclusions and outlook

Although the considerable heterogeneity in preclinical data and the so-far small number of available clinical datasets make it difficult to draw any definitive conclusions, we identified substantial design differences between preclinical and clinical trials, which may contribute to the modest efficacy of cell therapy in stroke patients and have important implications for future translational projects.

We propose several suggestions for preclinical studies which may prevent translational failure. First, in confirmatory preclinical studies, there should be greater similarity to patient populations likely to be treated in clinical trials. For example, use of aged male and female animals with comorbidities such as hypertension and diabetes would better reflect the clinical reality. Second, drug-cell interactions require further investigation. Third, permanent, instead of transient, stroke models might represent a more clinically relevant strategy when evaluating the efficacy of cell therapies<sup>54,55</sup>, particularly when targeting patient populations that cannot benefit from recanalization. Fourth, wider therapeutic time windows would benefit more patients. Hence, it would be beneficial to conduct more experimental studies testing cell transplantation in the subacute and chronic stroke stages. Fifth, it would be advantageous to devise a battery of sensory-motor function tests sensitive at detecting long-term impairment and conducive to repeated testing without developing compensatory strategies<sup>56</sup>. Last but not least, the therapeutic mechanisms of cell therapy still need to be clarified.

Several recommendations for clinical studies also emerge from our meta-analysis. First, freshly-harvested, autologous cells are recommended for future clinical trials to ensure maximal effects, if logistical challenges can be overcome. Second, studies of cell transplantation with more acute time windows (within 24h or 1 week) after stroke should be conducted, as these better resemble the situation in successful preclinical studies. Third, due to the extensive heterogeneity of the stroke patients, it will be crucial to identify the optimal recipients that are most likely to benefit from cell treatments, and to devise biomarkers that pinpoint such patients<sup>57</sup>. Last, multi-centered, randomized, double blinded clinical trials with larger sample sizes are urgently needed to evaluate the effect of cell therapy in stroke patients.

Finally, an illustration of comparability between preclinical and clinical studies by a similarity check list might help when translating a specific cell product from bench to clinic: 1) same time window (acute, subacute or chronic); 2) same delivery route; 3) same cell dose (number of cells per kg/body surface area); 4) same cell immunogenicity; 5) same preparation procedure before transplantation (e.g. fresh vs. cryopreservation); 6) same target infarcts (e.g., hemispherical infarcts of middle cerebral artery territory only, with or without reperfusion); 7) matched sex profile; 8) matched age; 9) same comorbidity; 10) same concomitant treatment.

## Acknowledgements

We thank the University of Eastern Finland Library for kind help while determining the optimal search strategy, Elina Hämäläinen for her assistance in reviewing the literature, and Mikko Myllyniemi for his contribution to data extraction. This work was supported by the RESSTORE project (grant 681044) ([www.resstore.eu](http://www.resstore.eu)). Li-li Cui was supported by a fellowship from the Faculty of Health Sciences, University of Eastern Finland and Finnish Cultural Foundation-Central Fund. Anna-Maija Tolppanen acknowledges the funding from the Academy of Finland (grants 295334 and 307232).

415  
416  
417  
418  
419  
420  
421  
422  
423

**Author Contributions**

LC, AT, JB and JJ contributed to the conception and design of the study; LC, DG, AT, JB and JJ contributed to the acquisition and analysis of data; LC, DG, AT, JB and JJ contributed to drafting the text and preparing the figures.

**Potential Conflict of Interest**

None.

## References

1. Li Y, Chopp M, Chen J, et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. *J Cereb Blood Flow Metab* 2000; 20:1311-1319.
2. Martino G, Pluchino S. The therapeutic potential of neural stem cells. *Nat Rev Neurosci* 2006; 7:395-406.
3. Eckert MA, Vu Q, Xie K, et al. Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. *J Cereb Blood Flow Metab* 2013; 33:1322-1334.
4. Wang J, Yu L, Jiang C, et al. Bone marrow mononuclear cells exert long-term neuroprotection in a rat model of ischemic stroke by promoting arteriogenesis and angiogenesis. *Brain Behav Immun* 2013; 34:56-66.
5. Moniche F, Gonzalez A, Gonzalez-Marcos JR, et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. *Stroke* 2012; 43:2242-2244.
6. Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. *Stem Cells* 2010; 28:1099-1106.
7. Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. *Lancet* 2016; 388:787-796.
8. Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol* 2017; 16:360-368.
9. Ramirez FD, Motazedian P, Jung RG, et al. Methodological rigor in preclinical cardiovascular studies: targets to enhance reproducibility and promote research translation. *Circ Res* 2017; 120:1916-1926.
10. Macleod MR, Fisher M, O'Collins V, et al. Good laboratory practice: preventing introduction of bias at the bench. *Stroke* 2009; 40: e50-e52.
11. Macleod MR, O'Collins T, Howells DW, et al. Pooling of animal experimental data reveals influence of study design and publication bias. *Stroke* 2004; 35: 1203-1208.
12. Vesterinen HM, Sena ES, Egan KJ, et al. Meta-analysis of data from animal studies: a practical guide. *J Neurosci Methods* 2014; 221:92-102.
13. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. *BMJ* 2011; 343: d5928.
14. Lees JS, Sena ES, Egan KJ, et al. Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis. *Int J Stroke* 2012; 7: 582-528.
15. Janowski M, Walczak P, Date I. Intravenous route of cell delivery for treatment of neurological disorders: a meta-analysis of preclinical results. *Stem Cells Dev* 2010; 19: 5-16.
16. Vu Q, Xie K, Eckert M, et al. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. *Neurology* 2014; 82:1277-1286.
17. Vahidy FS, Rahbar MH, Zhu H, et al. Systematic review and meta-analysis of bone marrow-derived mononuclear cells in animal models of ischemic stroke. *Stroke* 2016; 47:1632-1639.

18. Chen L, Zhang G, Gu Y, et al. Meta-analysis and systematic review of neural stem cells therapy for experimental ischemia stroke in preclinical studies. *Sci Rep* 2016; 6: 32291.
19. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. *Nature*. 1997; 390:350-351.
20. Cui LL, Kinnunen T, Boltze J, et al. Clumping and viability of bone marrow derived mesenchymal stromal cells under different preparation procedures: A flow cytometry-based in vitro study. *Stem Cells Int* 2016; 2016:1764938.
21. Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? *Stem Cells* 2014; 32:2430-2442.
22. François M, Copland IB, Yuan S, et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon- $\gamma$  licensing. *Cytotherapy* 2012; 14:147-152.
23. Weise G, Lorenz M, Pösel C, et al. Transplantation of cryopreserved human umbilical cord blood mononuclear cells does not induce sustained recovery after experimental stroke in spontaneously hypertensive rats. *J Cereb Blood Flow Metab* 2014; 34: e1-9.
24. Cruz FF, Borg ZD, Goodwin M, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. *Stem Cells Transl Med* 2015; 4:615-624.
25. Luetzkendorf J, Nerger K, Hering J, et al. Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. *Cytotherapy* 2015; 17:186-198.
26. Yang B, Parsha K, Schaar K, et al. Cryopreservation of bone marrow mononuclear cells alters their viability and subpopulation composition but not their treatment effects in a rodent stroke model. *Stem Cells Int* 2016; 2016: 5876863.
27. Lu WS, Li ZC, Tian ZM, et al. Clinical transplantation of human embryonic neural stem cells for the treatment of cerebral infarction sequelae. *Neurosurg* 2013; 23:58-60.
28. Chen J, Ye X, Yan T, et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats. *Stroke* 2011; 42:3551-3558.
29. Ortega FJ, Jolkkonen J, Mahy N, et al. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. *J Cereb Blood Flow Metab* 2013; 33: 356–364.
30. Pirzad Jahromi G, Seidi S, Sadr SS, et al. Therapeutic effects of a combinatorial treatment of simvastatin and bone marrow stromal cells on experimental embolic stroke. *Basic Clin Pharmacol Toxicol* 2012; 110: 487-493.
31. Ahnstedt H, McCullough LD, Cipolla MJ. The importance of considering sex differences in translational stroke research. *Transl Stroke Res*. 2016;7:261-273.
32. Sohrabji F, Park MJ, Mahnke AH. Sex differences in stroke therapies. *J Neurosci Res* 2017; 95:681-691.
33. Wagner DC, Bojko M, Peters M, et al. Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke. *Exp Transl Stroke Med* 2012; 4:17.

508 34. Alawieh A, Tomlinson S, Adkins D, et al. Preclinical and clinical evidence on ipsilateral  
509 corticospinal projections: implication for motor recovery. *Transl Stroke Res* 2017; 8: 529-  
510 540.

511 35. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behavior. *Nat Rev*  
512 *Neurosci* 2009; 10: 861-872.

513 36. Sutherland BA, Neuhaus AA, Couch Y, et al. The transient intraluminal filament middle  
514 cerebral artery occlusion model as a model of endovascular thrombectomy in stroke. *J Cereb*  
515 *Blood Flow Metab.* 2016; 36:363-369.

516 37. Ghali AA, Yousef MK, Ragab OA, et al. Intra-arterial infusion of autologous bone marrow  
517 mononuclear stem cells in subacute ischemic stroke patients. *Front Neurol* 2016;7:228.

518 38. Bhatia V, Gupta V, Khurana D, et al. Randomized assessment of the safety and efficacy of  
519 intra-arterial infusion of autologous stem cells in subacute ischemic stroke. *AJNR Am J*  
520 *Neuroradiol* 2018;39:899-904.

521 39. George PM, Steinberg GK. Novel stroke therapeutics: Unraveling stroke pathophysiology  
522 and its impact on clinical treatments. *Neuron* 2015; 87:297-309.

523 40. Wang LQ, Lin ZZ, Zhang HX, et al. Timing and dose regimens of marrow mesenchymal  
524 stem cell transplantation affect the outcomes and neuroinflammatory response after ischemic  
525 stroke. *CNS Neurosci Ther* 2014; 20: 317-326.

526 41. Boltze J, Schmidt UR, Reich DM, et al. Determination of the therapeutic time window for  
527 human umbilical cord blood mononuclear cell transplantation following  
528 experimental stroke in rats. *Cell Transplant* 2012; 21:1199-1211.

529 42. Toyoshima A, Yasuhara T, Kameda M, et al. Intra-arterial transplantation of allogeneic  
530 mesenchymal stem cells mounts neuroprotective effects in a transient ischemic stroke model  
531 in rats: Analyses of therapeutic time window and its mechanisms. *PLoS One* 2015; 10:  
532 e0127302.

533 43. Doeppner TR, Kaltwasser B, Teli MK, et al. Effects of acute versus post-acute systemic  
534 delivery of neural progenitor cells on neurological recovery and brain remodeling after focal  
535 cerebral ischemia in mice. *Cell Death Dis* 2014; 5: e1386.

536 44. Mitkari B, Nitzsche F, Kerkelä E, et al. Human bone marrow mesenchymal stem/stromal  
537 cells produce efficient localization in the brain and enhanced angiogenesis after intra-arterial  
538 delivery in rats with cerebral ischemia, but this is not translated to behavioral recovery.  
539 *Behav Brain Res* 2014; 259:50-59.

540 45. Yang B, Hamilton JA, Valenzuela KS, et al. Multipotent adult progenitor cells enhance  
541 recovery after stroke by modulating the immune response from the spleen. *Stem Cells* 2017;  
542 35: 1290-1302.

543 46. Boltze J, Arnold A, Walczak P, et al. The Dark Side of the Force - Constraints and  
544 Complications of Cell Therapies for Stroke. *Front Neurol* 2015; 6:155.

545 47. Yasuhara T, Matsukawa N, Hara K, et al. Notch-induced rat and human bone marrow stromal  
546 cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke  
547 animals. *Stem Cells Dev.* 2009;18:1501-14.

548 48. Steinberg GK, Kondziolka D, Wechsler LR, et al. Two-year safety and clinical outcomes in  
549 chronic ischemic stroke patients after implantation of modified bone marrow-derived  
550 mesenchymal stem cells (SB623): a phase 1/2a study. *J Neurosurg.* 2018:1-11.

49. Cui LL, Kerkelä E, Bakreen A, et al. The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. *Stem Cell Res Ther* 2015;6:11.
50. Cui LL, Nitzsche F, Pryazhnikov E, et al. Integrin  $\alpha 4$  overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection. *Stroke* 2017;48:2895-2900.
51. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. 2011;342:d549.
52. Antonic A, Sena ES, Lees JS, et al. Stem cell transplantation in traumatic spinal cord injury: A systematic review and meta-analysis of animal studies. *PLoS Biol*. 2013;11:e1001738.
53. Kanelidis AJ, Premer C, Lopez J, et al. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: A meta-analysis of preclinical studies and clinical trials. *Circ Res*. 2017; 120:1139-1150.
54. Corbett D, Carmichael ST, Murphy TH, et al. Enhancing the alignment of the preclinical and clinical stroke recovery research pipeline: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable translational working group. *Int J Stroke* 2017; 12: 462-471.
55. Modo MM, Jolkonen J, Zille M, et al. Future of animal modeling for poststroke tissue repair. *Stroke* 2018; 49:1099-1106.
56. Cui LL, Golubczyk D, Jolkonen J. Top 3 behavioral tests in cell therapy studies after stroke: difficult to stop a moving train. *Stroke* 2017; 48:3165-3167.
57. Boyd LA, Hayward KS, Ward NS, et al. Biomarkers of stroke recovery: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. *Neurorehabil Neural Repair* 2017; 31: 864-876.



## Figure Legends

Figure 1. PRISMA flowchart.

Figure 2. Effect sizes of (A) infarct size reduction, (B) mNSS, (C) rotarod test performance, and (D) ART performance in preclinical studies.

Figure 3. Funnel plot of (A) infarct size reduction, (B) mNSS, (C) rotarod test performance, and (D) ART performance in preclinical studies.

Figure 4. Study characteristics that significantly accounted for effect size heterogeneity in different outcome measures. (A) infarct size reduction: (i) cell immunogenicity; (ii) cell cryopreservation; (iii) use of animals with comorbidity; (iv) stroke model; (v) delivery time relative to stroke-onset. (B) mNSS: (i) cell cryopreservation; (ii) use of animals with comorbidity; (iii) delivery route; (iv) quality score of studies. (C) rotarod test: (i) cell immunogenicity; (ii) cell type. (D) ART: (i) cell immunogenicity; (ii) cell cryopreservation; (iii) use of animals with comorbidity. The dotted line indicates the pooled effect size of all studies.

Figure 5. Effect sizes of different outcome measures (mRS, mBI, NIHSS, and FMS) in clinical studies. Y: yes, N: no, Auto: autologous, Allo: allogeneic, Cryo: cryopreservation, N (T/C): number of patients (treated/control)

Figure 6. Subgroup analysis of mRS (A), mBI (B), NIHSS (C) and FMS (D) in clinical studies. (A-D): (i) cell type; (ii) cell immunogenicity; (iii) cell cryopreservation; (iv) delivery route; (v) randomization. The dotted line indicates the pooled effect size of all studies.

Figure 7. Study design discrepancies between preclinical and clinical studies: (A) immunogenicity of transplanted cells; (B) cell cryopreservation; (C) cell type; (D) comorbidities of stroke individuals; (E) age of stroke individuals; (F) sex profile; (G) time of cell transplantation.